
Long-term use of bisphosphonate is defined as greater than three years for the treatment of osteoporosis.[1][1] This type of fracture accounts for 1.1% of all femoral fractures, with an age-adjusted incidence rate of 1.8 to 113 cases per 100 000 person-years for bisphosphonate exposure of less than
Radiography, Bone Density Conservation Agents, Diphosphonates, Humans, Osteoporosis, Femoral Fractures
Radiography, Bone Density Conservation Agents, Diphosphonates, Humans, Osteoporosis, Femoral Fractures
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 25 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
